# EDGAR Filing Document

**Accession Number:** 0001213660
**File Stem:** 0001213900-23-002044
**Filing Date:** 2023-1
**Character Count:** 4742
**Document Hash:** 6ecd37804def2023cf5aa62c463c6cf3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-002044.hdr.sgml**: 20230110

**ACCESSION NUMBER**: 0001213900-23-002044

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230109

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230110

**DATE AS OF CHANGE**: 20230110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIMI International Medical Inc.
- **CENTRAL INDEX KEY:** 0001213660
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
- **IRS NUMBER:** 020563302
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34890
- **FILM NUMBER:** 23521462

**BUSINESS ADDRESS:**
- **STREET 1:** NO. 10, HUASHENG ROAD, FLOOR 21
- **STREET 2:** YUZHONG DISTRICT
- **CITY:** CHONGQING, P.R.
- **STATE:** F4
- **ZIP:** 404100
- **BUSINESS PHONE:** (8604) 1182209211

**MAIL ADDRESS:**
- **STREET 1:** NO. 10, HUASHENG ROAD, FLOOR 21
- **STREET 2:** YUZHONG DISTRICT
- **CITY:** CHONGQING, P.R.
- **STATE:** F4
- **ZIP:** 404100

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BOQI International Medical, Inc.
- **DATE OF NAME CHANGE:** 20191216

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NF Energy Saving Corp
- **DATE OF NAME CHANGE:** 20090825

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NF Energy Saving CORP of America
- **DATE OF NAME CHANGE:** 20070509

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 9, 2023**

---

| |
|:---|
| **BIMI International Medical Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-34890** | **02-0563302** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **9th Floor, Building 2, Chongqing Corporation Avenue,<br> Yuzhong District, Chongqing, P. R. China** | **116000** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(8604) 1182209211**

---

| |
|:---|
| **Not Applicable** |
| (Former name or former address, if changed since last report) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common stock, $0.001 par value BIMI | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events.**

On January 9, 2023, BIMI International Medical Inc.(the "Company") received formal notification from The Nasdaq Stock Market LLC confirming that the Company had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"), which requires that the Company's common stock maintain a minimum bid price of at least $1.00 per share, and that the matter is now closed.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: January 10, 2023 | **BIMI International Medical Inc.** | **BIMI International Medical Inc.** |
|  | By: | /s/ Tiewei Song |
|  | Name: | Tiewei Song |
|  | Title: | Chief Executive Officer |

---